Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced that the previously reported positive results from its Phase 1 safety trial of Progenza in patients with knee osteoarthritis have been published in the Journal of Translational Medicine.
The Board of Queensland Bauxite Limited (ASX:QBL) is pleased to announce that its subsidiary company Medical Cannabis Limited through its wholly owned subsidiary Medical Cannabis Research Group Pty Ltd, has signed a Research Funding Agreement with the Research & Development Foundation at the Technion Institute, Haifa, Israel.
Anatara Lifesciences (ASX:ANR) today released its Appendix 4D financial report for the half year ending 31st December 2017.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today released its Half-Year Report for the 6 months to 31 December 2017.
Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced that Progenza has been granted an Advanced Therapy Medicinal Product classification by the Committee for Advanced Therapies of the European Medicines Agency, following consultation with the European Commission.
Regeneus (ASX:RGS), a clinical-stage regenerative medicine technology company, today announced that the Japanese Patent Office has issued a decision to grant a patent covering the use of cancer vaccine technology for the treatment of a range of cancers in humans and animals.
Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced that topical use of Sygenus gel for 6 weeks in adults with acne was well tolerated and showed a significant effect on the appearance of acne lesions as early as 3 weeks.
